Neuren Pharmaceuticals |
High $12.50 |
Low $12.07 |
Trades 2,722 |
Turnover $3,205,258 |
Volume 261,029 |
| 30 June 2023 at 4:55pm | ||||
|
Market Cap (13-Nov) $2,999,472,128 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (6-Nov) 3,695,226 (2.91%) (131st) |
|
52w High $24.55 |
52w Low $10.92 |
P/E 42.02 |
EPS 0.15 |
Q4 2022 quarterly activity and cash flow report
NEU released this announcement to the ASX on 31 January 2023, 9:49. The announcement is marked as price sensitive, and is 10 page(s) in length and 278.86kb in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.139% short sold according to ASIC data. It was ranked the 436th most shorted stock on the ASX. It is now ranked as the 131st most shorted stock on the ASX with 2.915% of total shares short sold as of the latest reported data (06 November 2026).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Q4 2022 quarterly activity and cash flow report | 31 January 2023, 9:49 |
| Prader-Willi syndrome IND for NNZ-2591 approved by FDA | 23 January 2023, 9:31 |
| Neuren submits IND & first patients complete Phase 2 trials | 23 December 2022, 9:44 |
| Becoming a substantial holder | 7 December 2022, 10:23 |
If you were already registered, log in here.